传奥洛兹美医疗(HALO.US)将与默沙东(MRK.US)就注射版Keytruda展开专利战

智通财经2025-03-05

智通财经APP获悉，据报道，奥洛兹美医疗(HALO.US)与默沙东(MRK.US)之间正在酝酿一场新的专利纠纷，争议的焦点是抗癌重磅药物Keytruda的注射版。知情人士透露，奥洛兹美医疗认为默沙东侵犯了其专利，应该签订许可协议才能销售注射用Keytruda。默沙东的注射剂以韩国Alteogen公司开发的一种酶为基础，这是该公司应对即将到来的静脉注射Keytruda专利悬崖的解决方案。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2517912810?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-03-05 21:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517912810","market":"us","top_or_hot":-1,"title":"传奥洛兹美医疗(HALO.US)将与默沙东(MRK.US)就注射版Keytruda展开专利战","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，据报道，奥洛兹美医疗(HALO.US)与默沙东(MRK.US)之间正在酝酿一场新的专利纠纷，争议的焦点是抗癌重磅药物Keytruda的注射版。知情人士透露，奥洛兹美医疗认为默沙东侵犯了其专利，应该签订许可协议才能销售注射用Keytruda。默沙东的注射剂以韩国Alteogen公司开发的一种酶为基础，这是该公司应对即将到来的静脉注射Keytruda专利悬崖的解决方案。...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1258255.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>传奥洛兹美医疗(HALO.US)将与默沙东(MRK.US)就注射版Keytruda展开专利战</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n传奥洛兹美医疗(HALO.US)将与默沙东(MRK.US)就注射版Keytruda展开专利战\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-05 21:41 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1258255.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，据报道，奥洛兹美医疗(HALO.US)与默沙东(MRK.US)之间正在酝酿一场新的专利纠纷，争议的焦点是抗癌重磅药物Keytruda的注射版。知情人士透露，奥洛兹美医疗认为默沙东侵犯了其专利，应该签订许可协议才能销售注射用Keytruda。默沙东的注射剂以韩国Alteogen公司开发的一种酶为基础，这是该公司应对即将到来的静脉注射Keytruda专利悬崖的解决方案。...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1258255.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0965509101.SGD","symbol_name":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1258255.html","article_id":"2517912810","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517912810","pubTimestamp":1741182111,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，据报道，奥洛兹美医疗 与默沙东之间正在酝酿一场新的专利纠纷，争议的焦点是抗癌重磅药物Keytruda的注射版。知情人士透露，奥洛兹美医疗认为默沙东侵犯了其专利，应该签订许可协议才能销售注射用Keytruda。Keytruda几乎贡献了默沙东一半的总营收。默沙东去年表示，其注射版Keytruda在关键的3期试验中达到了主要目标。据报道，奥洛兹美医疗将在周三的投资者活动上讨论注射版Keytruda专利问题。截至发稿，默沙东盘前跌0.54%，奥洛兹美医疗涨0.81%。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","HALO":"奥洛兹美医疗","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","BK4534":"瑞士信贷持仓","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","BK4139":"生物科技","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","LU1917777945.USD":"安联专题基金Cl AT Acc","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","SG9999002232.USD":"Allianz Global High Payout USD","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","LU0238689110.USD":"贝莱德环球动力股票基金","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","BK4007":"制药","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","MRK":"默沙东"},"translate_title":"It is rumored that HALO.US will launch a patent war with Merck (MRK.US) over the injectable version of Keytruda","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HALO":1,"MRK":1},"content_text":"智通财经APP获悉，据报道，奥洛兹美医疗(HALO.US)与默沙东(MRK.US)之间正在酝酿一场新的专利纠纷，争议的焦点是抗癌重磅药物Keytruda的注射版。知情人士透露，奥洛兹美医疗认为默沙东侵犯了其专利，应该签订许可协议才能销售注射用Keytruda。默沙东的注射剂以韩国Alteogen公司开发的一种酶为基础，这是该公司应对即将到来的静脉注射Keytruda专利悬崖的解决方案。Keytruda几乎贡献了默沙东一半的总营收。Keytruda静脉注射版本将在2028年失去美国市场的独占权，届时将会出现更便宜的抗PD-1仿制药。默沙东去年表示，其注射版Keytruda在关键的3期试验中达到了主要目标。该公司去年还启动了一项监管程序，要求美国专利官员重新考虑授予奥洛兹美医疗的某些Mdase酶专利，因为这些专利的性质过于宽泛。据报道，奥洛兹美医疗将在周三的投资者活动上讨论注射版Keytruda专利问题。截至发稿，默沙东盘前跌0.54%，奥洛兹美医疗涨0.81%。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2517912810","isCrawlerRequest":true}